ABSTRACT
The mechanism of action for bevacizumab and the family of RTK inhibitors are depicted in Figure 1.
Figure 1 Novel antibody and small tyrosine kinase inhibitor therapies for ovarian cancer. These compounds are directed against circulating vascular endothelial growth factor (VEGF) (a.k.a. bevacizumab) and the VEGF receptor (sorafinib). In clinical trials, these therapies have demonstrated efficacy against ovarian cancer and hold promise as therapeutic options in the recurrent setting.
